← back to search

Simon L. Parsons

Galapagos (Belgium) · CA
Area of research
Surgery · Cancer Research
Research interest
Research interests include Esophageal Cancer Research and Treatment, Cancer Genomics and Diagnostics, Gastric Cancer Management and Outcomes, and Histone Deacetylase Inhibitors Research.
h-index
52
citations
20,543
works
214
NIH funding
primary concept
Medicine
email

Recent publications

Integrated epidemiological and molecular data inform the relationship between precancer and cancer states of esophageal adenocarcinoma
Nature Medicine 2026cited by 2position: middledoi
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer
Nature Cancer 2025cited by 17position: middledoi
Disentangling oncogenic amplicons in esophageal adenocarcinoma
Nature Communications 2024cited by 20position: middledoi
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial
˜The œLancet. Gastroenterology & hepatology 2023cited by 166position: middledoi
Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma
Nature Communications 2023cited by 24position: middledoi
A decade of the Oesophageal Cancer Clinical and Molecular Stratification Consortium
Nature Medicine 2023cited by 4position: middledoi
Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts
Cell Reports Medicine 2022cited by 24position: middledoi
Risk Prediction Model of 90-Day Mortality After Esophagectomy for Cancer
JAMA Surgery 2021cited by 105position: middledoi
Outcomes after totally minimally invasive <i>versus</i> hybrid and open Ivor Lewis oesophagectomy: results from the International Esodata Study Group
British journal of surgery 2021cited by 54position: middledoi
Modulation of the Tumor Promoting Functions of Cancer Associated Fibroblasts by Phosphodiesterase Type 5 Inhibition Increases the Efficacy of Chemotherapy in Human Preclinical Models of Esophageal Adenocarcinoma
SSRN Electronic Journal 2021cited by 0position: middledoi
Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
ePrints Soton (University of Southampton) 2021cited by 0position: middledoi
Modulation of the tumour promoting functions of cancer associated fibroblasts by phosphodiesterase type 5 inhibition increases the efficacy of chemotherapy in human preclinical models of esophageal adenocarcinoma
Zenodo (CERN European Organization for Nuclear Research) 2021cited by 0position: middledoi
Identification of Subtypes of Barrett’s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data
Gastroenterology 2020cited by 108position: middledoi
Patient-specific cancer genes contribute to recurrently perturbed pathways and establish therapeutic vulnerabilities in esophageal adenocarcinoma
Nature Communications 2019cited by 47position: middledoi
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma
British journal of surgery 2017cited by 107position: middledoi
Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma
Nature Genetics 2015cited by 316position: middledoi
British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus
Gut 2013cited by 1,339position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Andrew Cowie · University of Southampton4 papers (2021–2022)Tim Underwood · NIHR Southampton Respiratory Biomedical Research Unit4 papers (2021–2022)Benjamin P. Sharpe · University of Southampton4 papers (2021–2022)Anna M. Grabowska · University of Nottingham4 papers (2021–2022)Stella P. Breininger · University of Southampton4 papers (2021–2022)J. Saunders · University of Nottingham4 papers (2021–2022)Spiros D. Garbis · Broadata Communications (United States)4 papers (2021–2022)Antigoni Manousopoulou · University of Southampton4 papers (2021–2022)Robert Walker · University of Southampton4 papers (2021–2022)Matthew Rose‐Zerilli · University of Southampton4 papers (2021–2022)Pamela Collier · University of Leicester4 papers (2021–2022)Jack Harrington · University of Southampton4 papers (2021–2022) · 4 papers (2021–2022)Alison Ritchie · University of Nottingham4 papers (2021–2022)Fereshteh Izadi · Swansea University4 papers (2021–2022)Philip A. Clarke · Indiana University School of Medicine4 papers (2021–2022)Annette Hayden · University of Southampton4 papers (2021–2022)Zoë S. Walters · University of Southampton2 papers (2021–2022) · 1 papers (2013–2013)Maria O’Donovan · University of Cambridge1 papers (2013–2013)